EBEman El Bana

Eman El Bana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eman El Bana has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Biological Impacts of Sitagliptin on the Pancreas of a Rat Model of Type 2 Diabetes Mellitus: Drug Interactions with Metformin

    by Lamiaa M. Shawky, Ahmed A. Morsi, Eman El Bana, Safaa Masoud Hanafy

    Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is a beneficial class of antidiabetic drugs. However, a major debate about the risk of developing pancreatitis is still existing. The aim of the work was to study the histological and immunohistochemical effects of sitagliptin on both endocrine and exocrine pancreases in a rat model of type 2 diabetes mellitus and to correlate these effects with the biochemical findings. Moreover, a possible synergistic effect of sitagliptin, in combination with metformin, was also evaluated. Fifty adult male rats were used and assigned into five equal groups. Group 1 served as control. Group 2 comprised of untreated diabetic rats. Group 3 diabetic rats received sitagliptin. Group 4 diabetic rats received metformin. Group 5 diabetic rats received both combined. Treatments were given for 4 weeks after the induction of diabetes. Blood samples were collected for biochemical assay before the sacrification of rats. Pancreases were removed, weighed, and were processed for histological and immunohistochemical examination. In the untreated diabetic group, the islets appeared shrunken with disturbed architecture and abnormal immunohistochemical reactions for insulin, caspase-3, and inducible nitric oxide synthase (iNOS). The biochemical findings were also disturbed. Morphometrically, there was a significant decrease in the islet size and islet number. Treatment with sitagliptin, metformin, and their combination showed an improvement, with the best response in the combined approach. No evidence of pancreatic injury was identified in the sitagliptin-treated groups. In conclusion, sitagliptin had a cytoprotective effect on beta-cell damage. Furthermore, the data didn’t indicate any detrimental effects of sitagliptin on the exocrine pancreas.


  • The possible protective effect of quercetin on methotrexate induced hepatotoxicity in albino rats: biochemical , histological and immunohistochemical study

    by Eman El Bana, Kamal M. Kamal

    Background:Methotrexate(Mtx) is an antineoplastic and immunosuppressive drug. That may cause hepatotoxicity, whereas quarcetin has anti-inflammatory and antiproliferative properties.Aim of the work: This study aimed to investigate the possible protective and therapeutic effects of quercetin against methotrexate (Mtx)-induced hepatotoxicity with biochemical and histopathological studies in ratsMaterials and methods: twenty six Wister albino rats were equally divided into four experimental groups: Control (group I), Mtx group (group II) rats received (single dose of Mtx 20 mg/kg i.p.). QCT protective group (group III) rats pre-treated with QCT (20 mg/kg orally daily for 7 days then Mtx administration. QCT therapeutic group (group IV) rats cotreated with Mtx(20 mg/kg for i.p, single dose)then QCT were given as before .Following treatment, the animals were sacrificed, and liver tissue samples were histopathologically evaluated using H&E, Masson's, PCNA staining, and serum transaminases were measured and statistically compared across all groupsResults:Group II (Mtx group) demonstrated hydrobic degeneration of hepatocytes, congestion of hepatic sinusoids ,central veins and portal veins .An apparent increase in collagenous fibers distribution around the central vein and portal tract was detected .In groups III (protected QCT), and group IV (QCT therapeutic groups), showed less histological injury compared to Mtx group as regards liver sections ,but pretreatment with QCT in group III was more effective than in group IV except for mild dilation of sinusoids Conclusion: Methotrexate has a deleterious effect on the liver. Quaricetin may be a potential adjuvant drug to reduce the hepatic side effects observed during Mtx therapy for various clinical conditions.


  • Open Access

    MORPHOMETRIC STUDY OF THE STERNUM IN EGYPTIAN PERSONS BY CT SCAN (FROM 10 TO MORE THAN 60 YEARS OLD)

    by Essam Mohammed Eid, Gamal Elsayed Abd-Elsalam, Kamal M. Kamal, Eman El Bana, Hind Hamdy

  • Open Access

    The appropriate time for stem cell transplantation in albino rat with amiodarone induced lung fibrosis: histological and immunohistochemical study

    by Eman El Bana, Lamiaa Shawky

    Background: The fibrosing form of lung injury had bad progressive course and lethal outcome.Aim of the work: This study throws light on the possible protective and/or therapeutic consequence of mesenchymal stem cell therapy in lung fibrosis induced by amiodarone in albino rat. In addition to study the possible recovery of damaged lung after amiodarone withdrawal. Material & Methods: Forty five adult male albino rats were divided into five equal groups. Group I (control); group II (amiodarone) received amiodarone 30 mg/kg orally for 6 days /week for 6 weeks, group III (withdrawal); group IV (early stem cell) mesenchymal stem cell was administrated after 1st dose of amiodarone therapy ; group VI (late stem cell) mesenchymal stem cell was administrated immediately after amiodarone suspension . Lung samples were processed and examined using histological and immunohistochemical techniques and the obtained data was subjected to statistical analysis.Results: Amiodarone treated group displayed obstructed bronchioles, collapsed alveoli, inflammatory cell infiltration ,thickened interalveolar septa and pulmonary vessels wall. Increased collagen fibers deposition between alveoli and around blood vessels in addition to highly expressed caspase-3. Group III (withdrawal) recorded only mild improvement. Group IV (early stem cell therapy ) showed advanced improvement of pulmonary alveolar architecture, on other side group V (late stem cell therapy)revealed moderate improvement of lung injury.Conclusion: The majority of amiodarone lung toxicity manifestations and lung fibrosis were regressed by bone marrow derived mesenchymal stem cell (BMSCs) therapy and the best result obtained when stem cell initiated early in the development of pathogenesis.